Brought to you by 
KalVista raises £8mm through its Series A round; spins off from Vantia Therapeutics
09 Sep 2011
Executive Summary
Vantia Therapeutics Ltd. has spun off KalVista Pharmaceuticals Ltd., a newly formed company co-founded with experts from Harvard Medical School that is focused on diabetic macular edema (DME). KalVista simultaneously raised £8mm ($13.2mm) through its Series A venture round to Novo AS and SV Life Sciences. (These were the two backers that supported the spin-off of Vantia from Ferring Pharmaceuticals AS about three years ago.)
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Spin-Off
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
KalVista raises £8mm through its Series A round; spins off from Vantia Therapeutics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice